Status:
COMPLETED
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE1
Brief Summary
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
Eligibility Criteria
Inclusion
- Diagnosis of AD
- Age 50-85
- MMSE 14-26
- Other Inclusion Criteria Apply
Exclusion
- Significant Neurological Disease
- Major Psychiatric Disorder
- Clinically Significant Systemic Illness
- Other Exclusion Criteria Apply
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00397891
Start Date
October 1 2006
End Date
February 1 2010
Last Update
September 4 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Chiba, Japan
2
Pfizer Investigational Site
Saitama, Japan
3
Pfizer Investigational Site
Shizuoka, Japan
4
Pfizer Investigational Site
Tokyo, Japan